טוען...
Favorable Immunotherapy Plus Tyrosine Kinase Inhibition Outcome of Renal Cell Carcinoma Patients with Low CDK5 Expression
PURPOSE: Immunotherapy (IO) plus tyrosine kinase inhibitor (TKI) has become the first-line treatment for advanced renal cell carcinoma, despite the lack of prognostic biomarkers. Cyclin-dependent kinase 5 (CDK5) affects the tumor microenvironment, which may influence the efficacy of TKI+IO. MATERIAL...
| Autores principales: | , , , , , |
|---|---|
| פורמט: | Online Artículo Texto |
| שפה: | English |
| יצא לאור: |
Korean Cancer Association
2023
|
| נושאים: | |
| גישה מקוונת: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10582544/ https://www.ncbi.nlm.nih.gov/pubmed/37024096 http://dx.doi.org/10.4143/crt.2022.1532 |